The team behind EVmiRED, led by researchers at Sun Yat-Sen University in Guangzhou, China, published the work in the journal Advanced Biotechnology. Their database integrates two kinds of information that had never been systematically combined before: how abundant each microRNA is inside extracellular vesicles, and how often specific positions within those microRNAs have been chemically altered. The current release covers 683 samples drawn from 12 tumor types and cell lines, most of them derived from human plasma, the liquid portion of blood in which vesicles circulate throughout the body.

To understand why this matters, it helps to know what microRNAs do. These are short RNA molecules, roughly 22 chemical letters long, that act as genetic volume knobs. By binding to messenger RNAs, the working copies of genes, microRNAs can trigger their destruction or block their translation into proteins. Because a single microRNA can regulate hundreds of target genes, even small changes to its sequence can ripple through entire gene networks. Disrupted microRNA function is a hallmark of cancer, and microRNAs carried by tumor-derived vesicles can even reprogram non-metastatic cells into metastatic ones.

But microRNAs are not fixed scripts. Enzymes called ADARs can chemically convert adenosine, one of the four RNA letters, into inosine, which the cellular machinery reads as guanosine. This adenosine-to-inosine editing, or A-to-I editing, can change how a microRNA precursor is processed, how stable the mature molecule is, and, most consequentially, which genes it targets. The seed region of a microRNA, positions 2 through 8, does most of the target recognition work, and editing there can be transformative. Previous research found that the overlap between predicted mRNA targets before and after editing averages only about 3 percent, meaning a single editing event can essentially rewire the microRNA’s entire regulatory network.

Despite this power, editing events in vesicle-borne microRNAs had barely been cataloged. Before this study, only 11 editing sites had ever been reported in extracellular vesicle microRNAs. Existing vesicle databases such as Vesiclepedia, ExoCarta, and EVpedia list vesicle contents but say nothing about editing, while resources like EVmiRNA and EVAtlas track microRNA abundance without capturing chemical modifications. EVmiRED closes that gap, and dramatically so: its analysis pipeline identified 151 edited sites, roughly 15 percent of all editing events cataloged in the curated reference database MiREDiBase, with a median of 22 editing sites detected per sample.

Detecting editing in mature microRNAs is technically brutal. Because the molecules are so short, sequencing reads carrying mismatches map poorly to the reference genome, making genuine edits hard to distinguish from sequencing errors. The team sidestepped this problem by anchoring their search to a set of high-confidence editing sites previously identified with a method called miR-mmPCR-seq. They built custom reference databases of edited pre-microRNAs, in which adenosines at known editing positions were replaced with guanosines, and then aligned cleaned sequencing reads first against unedited references and then against edited ones. Only sites supported by at least two editing reads, editing levels of at least 5 percent, and statistically significant modification relative to the sequencing error rate made the cut.

The quality controls were equally strict. Datasets were filtered according to guidelines from the International Society for Extracellular Vesicles, and reads with too many ambiguous bases, abnormal lengths, or poor quality scores were discarded. Any dataset retaining fewer than one million clean reads was excluded. Expression levels were normalized to reads per million, and batch effects arising from different sequencing platforms were corrected using a statistical tool called pyComBat, with both raw and corrected values made available to users.

The results revealed a striking pattern. Within plasma-derived samples, the team identified 86 high-confidence editing sites, and editing events clustered most frequently at positions 2 and 5, both inside the seed region where target recognition happens. Even more surprising, 84 of those 86 sites sat on the 5p strand of microRNAs. Although 5p microRNAs make up only 29 percent of the expressed high-confidence vesicle microRNAs, they harbor the overwhelming majority of editing events. In cellular microRNAs, the researchers’ earlier work had found no such strand bias, hinting that vesicles possess additional, still-unidentified regulatory mechanisms that govern which strand gets edited.

A case study built into the database demonstrates its diagnostic potential. Analyzing a public plasma dataset, the researchers used principal component analysis to show that microRNA editing profiles cleanly separated healthy individuals from cancer patients. Specific events stood out: position 2 of hsa-miR-181a-5p showed significantly increased seed-region editing in colorectal cancer compared with healthy controls, while the same position in hsa-miR-455-5p showed a significant decrease. In prostate cancer, position 1 of hsa-miR-100-5p, located in the 5′ anchor region, showed elevated editing. Target predictions run separately on unedited and edited sequences indicated that these seed-region changes could substantially alter which genes each microRNA silences.

The web interface at evmired.sysu.edu.cn is designed for researchers without bioinformatics expertise, offering search, comparison, and download modules that let users query individual microRNAs, visualize expression and editing patterns, and compare predicted mRNA targets before and after editing. The authors caution that their conservative strategy, restricted to previously reported editing sites, likely represents a lower bound on the true extent of vesicle microRNA editing. Future versions aim to discover novel events by generating matched pre-microRNA and vesicle sequencing data, expand coverage to more cancer subtypes and disease stages, and incorporate longitudinal samples collected before, during, and after therapy. If those efforts succeed, the hidden edits riding inside cancer’s tiny messengers could become powerful signals in liquid biopsies for early detection, treatment monitoring, and personalized oncology.

Subject of Research: A curated database of microRNA editing events in extracellular vesicles across human cancers

Article Title: EVmiRED: a curated database of miRNA editing landscape in extracellular vesicles

Article References: Kou, K., Wen, L., Yang, L., Gao, Z., Jin, B., Pan, J., & Zhang, R. (2026). EVmiRED: a curated database of miRNA editing landscape in extracellular vesicles. Advanced Biotechnology, 4(2), Article 13. https://doi.org/10.1007/s44307-026-00107-w

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00107-w

Keywords: extracellular vesicles, microRNA, RNA editing, ADAR, cancer biomarkers, liquid biopsy, exosomes, metastasis, seed region, small RNA sequencing, EVmiRED, oncology

A-to-I RNA editing is catalyzed by the ADAR family of enzymes, primarily ADAR1 and ADAR2, which chemically convert adenosine bases to inosine within RNA transcripts. Because the cellular machinery reads inosine as guanosine, this single change can rewrite the meaning of a gene: it can swap amino acids in proteins, alter splice sites, create or destroy start and stop codons, reshape RNA folding, and modulate microRNA targeting. In humans, millions of editing sites dot the transcriptome, with the vast majority clustered in repetitive elements such as Alu sequences, where paired inverted repeats form the double-stranded RNA substrates that ADAR enzymes prefer. Editing in these repetitive regions also helps cells distinguish their own RNA from foreign double-stranded RNA, preventing inappropriate immune activation.

The functional stakes are high. Aberrant A-to-I editing has been implicated in amyotrophic lateral sclerosis, autism spectrum disorder, schizophrenia, epilepsy, depression and multiple cancers, and dynamic editing levels are known to vary across tissues, developmental stages and species. Because editing levels, defined as the fraction of adenosines converted to inosine at a given site, are the currency of nearly every study in this field, accurate measurement is foundational. Yet while considerable effort has gone into developing methods to identify editing sites from sequencing data, far less attention has been paid to whether the quantification of editing levels itself is trustworthy.

To test this, the team, led by Shi Cheng and Yulong Song of Guangzhou Medical University alongside colleagues at Sun Yat-sen University, performed matched short-read and long-read cDNA RNA sequencing on two human cell lines, HEK293T and U2OS. The short-read data were generated on an Illumina NovaSeq 6000 platform using both polyA-selected and rRNA-depleted library strategies, producing reads of roughly 150 nucleotides. The long-read data were produced on Oxford Nanopore Technologies PromethION sequencers, which capture full-length cDNA molecules with median clean read lengths of 812 to 878 nucleotides. Both approaches were anchored to a curated reference list of 2,858,028 human A-to-I editing sites compiled from the group’s previous work.

The results were striking. In HEK293T cells, long-read sequencing identified 3,897 editing sites measured significantly higher than by polyA-selected short-read sequencing, against only 445 sites measured higher by the short-read approach, an approximately 8.8-fold difference in the number of sites. Globally, the median editing level estimated by long reads was about 2.3 times that from short reads. The pattern held for sites in Alu elements, in repetitive non-Alu regions and in nonrepetitive regions alike. Most dramatically, at nonrepetitive sites the median short-read estimate was 0 percent, implying no editing at all, whereas long-read sequencing revealed a true median level of about 2.1 percent. Parallel comparisons using rRNA-depleted short-read libraries, and independent experiments in U2OS cells, reproduced the same directional bias, with long reads detecting roughly 6.6 to 9.0 times more significantly higher-measured sites.

To rule out artifacts, the researchers ran an extensive battery of controls. They raised coverage thresholds from 30 to 40, 50 and 60 reads per site, tightened the base-quality cutoff for long reads, and removed PCR duplicate reads; the underestimation by short reads persisted in every case. As expected, no meaningful difference emerged between polyA-selected and rRNA-depleted short-read libraries, or between the two cell lines, confirming that the bias tracks with sequencing technology rather than biology. A full-length DNA and RNA amplicon sequencing experiment provided direct validation: DNA amplicons, which cannot carry RNA edits, showed editing levels near zero, while RNA amplicons and long-read cDNA sequencing agreed with each other and both substantially exceeded the short-read estimates.

The mechanistic explanation converged on read length and its effect on genome alignment. Because short reads carry less sequence context, they are more likely to map to the wrong place in the reference genome, particularly within repetitive regions where many loci look alike. By computationally constructing artificial short-read datasets of 50, 75, 100 and 150 nucleotides from their own 150-nucleotide data, the team showed a strongly positive correlation between read length and measured editing level: longer reads yielded higher estimates, with fold differences reaching 12.1 between 150-nt and 50-nt reads. Crucially, when they truncated reads at the alignment stage rather than the sequence stage, recalculating mapping coordinates so that no re-alignment occurred, the correlation vanished. This pinpointed misalignment, not any property of the sequences themselves, as the culprit.

The alignment analysis went further. As read lengths decreased, millions of reads shifted from uniquely mapped to multiply mapped or unmapped statuses, and the counts of these misalignment categories correlated negatively with measured editing levels and with the Alu editing index, a widely used global metric computed with the RNAEditingIndexer tool. The same positive relationship between read length and editing quantification appeared in public short-read data from HEK293T, U2OS, HeLa, HepG2, K562, A549 and U87 cells, and in artificial datasets derived from long-read data segmented to shorter lengths, indicating the effect is universal across platforms and laboratories.

The generality of the finding was then tested against independent public resources. A paired short-read and long-read dataset covering eight human lung cancer cell lines showed higher editing quantification by long reads in every line, with nonrepetitive sites again registering zero percent under short reads versus roughly two percent under long reads. Cross-study comparisons using long-read data from GM12878 and HeLa cells against ENCODE and other short-read datasets revealed 23.8-fold and 6.4-fold excesses, respectively, of sites measured higher by long reads. The authors conclude that long-read RNA sequencing is preferable for accurate quantification of A-to-I editing levels, while acknowledging its higher cost; for laboratories constrained to short reads, they recommend raising coverage depth, restricting analyses to uniquely mapped reads, or validating key sites with full-length amplicon or Sanger sequencing.

Beyond editing, the study raises a caution for transcriptomics at large. Since read-length-dependent misalignment degrades any measurement that depends on precise genomic placement, splicing and gene expression estimates from short-read data may also harbor systematic errors that warrant closer scrutiny. Given that A-to-I editing shapes nearly 85 percent of the human transcriptome and is an emerging target for RNA-based therapeutics, the message is clear: the technology chosen to read RNA does not merely observe biology, it shapes what biology appears to say.

Subject of Research: Comparison of short-read and long-read RNA sequencing for accurate quantification of A-to-I RNA editing levels

Article Title: Short-read RNA-seq yields lower estimates of A-to-I RNA editing levels than long-read cDNA sequencing

Article References: Cheng, S., Qi, Y., Ya, J., Xia, L., Zhang, W., Xiong, Q., Liu, Q., Zhang, J., & Song, Y. (2026). Short-read RNA-seq yields lower estimates of A-to-I RNA editing levels than long-read cDNA sequencing. Advanced Biotechnology, 4(3), Article 27. https://doi.org/10.1007/s44307-026-00123-w

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00123-w

Keywords: A-to-I RNA editing, RNA-seq, short-read sequencing, long-read sequencing, ADAR, alignment accuracy, read length, transcriptome, Alu repeats, cancer cell lines, Oxford Nanopore, quantification bias